Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.95 Insider Own0.90% Shs Outstand158.96M Perf Week-5.93%
Market Cap7.01B Forward P/E61.29 EPS next Y0.72 Insider Trans-13.24% Shs Float155.71M Perf Month-27.35%
Income-144.60M PEG- EPS next Q-0.07 Inst Own- Short Float5.78% Perf Quarter-25.10%
Sales903.40M P/S7.75 EPS this Y31.50% Inst Trans0.90% Short Ratio6.82 Perf Half Y-10.92%
Book/sh7.82 P/B5.64 EPS next Y1231.48% ROA-9.00% Target Price55.45 Perf Year-22.68%
Cash/sh2.73 P/C16.16 EPS next 5Y- ROE-13.10% 52W Range41.15 - 71.22 Perf YTD-19.48%
Dividend- P/FCF- EPS past 5Y-48.30% ROI-10.10% 52W High-38.12% Beta1.72
Dividend %- Quick Ratio2.50 Sales past 5Y9.40% Gross Margin82.90% 52W Low7.10% ATR2.24
Employees2000 Current Ratio2.80 Sales Q/Q29.00% Oper. Margin-16.40% RSI (14)34.59 Volatility3.41% 4.67%
OptionableYes Debt/Eq0.23 EPS Q/Q116.40% Profit Margin-17.50% Rel Volume0.66 Prev Close44.37
ShortableYes LT Debt/Eq0.23 EarningsApr 26 BMO Payout- Avg Volume1.32M Price44.07
Recom2.70 SMA20-4.99% SMA50-19.06% SMA200-17.37% Volume872,671 Change-0.68%
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Apr-23-18 11:16AM  Is Alkermes' Promising Depression Drug Back On Track? Motley Fool
Apr-22-18 10:50AM  Johnson & Johnson's First-Quarter 2018 Earnings Review Motley Fool
Apr-19-18 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results PR Newswire
Apr-18-18 10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks
07:30AM  Wired News FDA Accepts NDA Review for Alkermes ALKS 5461 for Treatment of Major Depressive Disorder ACCESSWIRE
Apr-17-18 06:33PM  Alkermes Rallies as FDA Accepts NDA for Depression Drug Zacks
08:45AM  Company News For Apr 17, 2018 Zacks
Apr-16-18 07:01PM  Cramer's lightning round: Take a long-term view on Spotif... CNBC Videos
06:50PM  Cramer's lightning round: Take a long-term view on Spotify CNBC
01:31PM  Alkermes Wins Quick Reversal From FDA on Antidepressant Drug TheStreet.com
11:18AM  Is It Time to Give Up on Alkermes? Motley Fool
07:27AM  Alkermes's stock soars after FDA accepts NDA review, 2 weeks after refusing MarketWatch
06:50AM  Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
Apr-11-18 09:37AM  Alkermes Has Some Decisions to Make Motley Fool
Apr-10-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Alkermes plc, Net 1 UEPS Technologies, CoreCivic, Inc., Videocon d2h, Shinhan Financial Group, and Himax Technologies Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-07-18 04:13PM  Will Shire Be Bought Out? Motley Fool
Apr-05-18 10:19AM  FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus Zacks
Apr-04-18 09:00PM  Alkermes' Bad News Could Be Good News for Johnson & Johnson Motley Fool
10:56AM  Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion Zacks
Apr-03-18 03:23PM  Alkermes Sinks as FDA Refuses Depression Drug Review Zacks
10:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc Business Wire
10:13AM  Company News For April 3, 2018 Zacks
08:16AM  Alkermes execs say theyre flummoxed by embarrassing FDA drug refusal; stock plunges MarketWatch
08:10AM  Todays Research Reports on Stocks to Watch: Alkermes and Teva ACCESSWIRE
06:24AM  Drugmaker Alkermes confirms expansion, hiring plans in Waltham American City Business Journals
Apr-02-18 05:04PM  What Happened in the Stock Market Today Motley Fool -21.96%
04:10PM  Alkermes Plunges After FDA Refuses To Review Depression Drug Investor's Business Daily
04:10PM  Dow Comes Off Session Lows, Finishes Day Down More Than 400 Points TheStreet.com
02:54PM  Alkermes FDA Refusal: Biotech ETFs Dragged Down ETF Trends
01:22PM  Biotech Salvage Operations Come With Red Flags Bloomberg
01:21PM  Alkermes Surprised, Angered by FDA Rejection of Antidepressant TheStreet.com
11:35AM  Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today Motley Fool
10:27AM  FDA refuses to review Alkermes' depression treatment, seeks more trials Reuters
08:47AM  FDA rejects Alkermes depression drug application CNBC Videos
08:32AM  Biotech stock Alkermes plunges 20% after FDA refuses to review its depression treatment CNBC
08:12AM  Alkermes shares tumble 22% after FDA 'refusal' letter for depression treatment MarketWatch
07:15AM  FDA rejects application to review Alkermes' depression treatment Reuters
07:00AM  Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 PR Newswire
Mar-26-18 05:13PM  Trump's Opioid Plan Gives Alkerme's Vivitrol Drug a Sales Boost TheStreet.com
Mar-19-18 06:12PM  Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook Moody's
Mar-14-18 08:00AM  Research Report Identifies Barrick Gold, Atlassian, Marvell Technology Group, Orix Corp Ads, Alkermes plc, and Sierra Wireless with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-05-18 04:00PM  Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences PR Newswire
Mar-01-18 10:26PM  5 Stocks the World Really Needs Right Now: A 1-Year Performance Review Motley Fool
07:00AM  Alkermes Appoints James Robinson as President and Chief Operating Officer PR Newswire
Feb-28-18 06:10PM  You Gotta Know the Lingo, Volume 3: Investing Terms Every Fool Should Understand Motley Fool
Feb-23-18 06:00AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Feb-22-18 03:52PM  Why Alkermes Is Sinking Today Motley Fool -10.51%
09:04AM  The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes Benzinga
Feb-21-18 12:49PM  Biotech Alkermes May Surge On Wave of New Drugs Investopedia
Feb-20-18 08:45AM  Alkermes Sets Itself Up for a "Transformative" 2018 Motley Fool
Feb-17-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-16-18 08:48AM  Alkermes PLC (ALKS) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com +5.51%
07:20AM  Blog Exposure - FDA Accepted New Drug Application Submitted by Valeant Pharma's Ortho Dermatologics for JEMDEL(TM) Plaque Psoriasis Treatment ACCESSWIRE
Feb-15-18 03:01PM  Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates Zacks +7.52%
Feb-14-18 03:51PM  Here's Why Alkermes Spiked Today Motley Fool +8.41%
10:05AM  Alkermes reports 4Q loss Associated Press
08:55AM  Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? Zacks
08:00AM  Alkermes Appoints Shane Cooke to Board of Directors PR Newswire
07:00AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018 PR Newswire
06:45AM  Alkermes Plc to Host Earnings Call ACCESSWIRE
Feb-12-18 08:44AM  Why Earnings Season Could Be Great for Alkermes (ALKS) Zacks
Feb-07-18 04:01PM  Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results PR Newswire
Feb-06-18 01:09PM  5 Biotech Stocks Set to Trump Estimates This Earnings Season Zacks
Feb-05-18 04:32PM  This Explains Why Alkermes Plc Is Falling Today Motley Fool -12.18%
04:30PM  Why Wells Fargo, Advanced Micro Devices, and Alkermes Slumped Today Motley Fool
09:43AM  Heres Why Alkermes Plc Is Moving Now Market Exclusive
08:35AM  Strength Seen in Alkermes (ALKS): Stock Soars 8.7% Zacks
06:52AM  5 Opioid Treatment Stocks Insider Monkey
Feb-01-18 09:08AM  Alkermes Submits NDA for Depression Candidate to the FDA Zacks
Jan-31-18 02:00PM  Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder PR Newswire
Jan-29-18 07:02AM  3 Biotech Stocks to Buy for 2018 Motley Fool
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
Jan-22-18 11:10AM  DEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS ACCESSWIRE
10:34AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 ACCESSWIRE
Jan-18-18 01:55PM  3 Biotech Stocks Start Healthy in 18: Will the Rally Last? InvestorPlace
01:00PM  The Klein Law Firm Reminds Investors of a Class Action on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ALKS) ACCESSWIRE
10:27AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 ACCESSWIRE
Jan-17-18 08:47PM  Netflix, Inc. (NFLX), General Electric Company (GE): Mott Capital Managements Top Winners and Losers of 2017 Insider Monkey
06:08PM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm Business Wire
04:36PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS ACCESSWIRE
02:34PM  FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc (Nasdaq: ALKS) To Contact The Firm GlobeNewswire
01:12PM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of January 22 Deadline in Securities Class Action Against Alkermes plc (ALKS) Business Wire
08:23AM  BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day Zacks
Jan-16-18 03:11PM  3 Biotech Stocks Start Healthy in '18: Will the Rally Last? Zacks
11:34AM  ALKS UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018 ACCESSWIRE
10:34AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 ACCESSWIRE
Jan-15-18 11:00AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS ACCESSWIRE
08:15AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 Zacks
Jan-13-18 08:29AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKS ACCESSWIRE
Jan-12-18 08:08AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Jan-11-18 08:00PM  The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018 GlobeNewswire
Jan-10-18 06:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKS ACCESSWIRE
03:00PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS ACCESSWIRE
Jan-09-18 06:23PM  ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm Business Wire +5.65%
02:07PM  Alkermes Is Getting Ready for a Rally TheStreet.com
11:34AM  ALKS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018 GlobeNewswire
10:33AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 ACCESSWIRE
08:08AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
06:36AM  Alkermes: Cramer's Top Takeaways TheStreet.com
Jan-08-18 07:23PM  Alkermes CEO: 'Best days are still ahead' for opioid addi... CNBC Videos
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorApr 02Option Exercise8.981,0008,9801,000Apr 04 06:41 PM
MITCHELL PAUL JDirectorApr 02Sale46.751,00046,7500Apr 04 06:41 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 03Option Exercise0.001,250022,264Mar 05 05:35 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 03Option Exercise0.003,500041,756Mar 05 05:46 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250087,602Mar 05 05:55 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise0.002,813085,369Mar 05 06:02 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 03Option Exercise0.001,250036,732Mar 05 06:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8130173,598Mar 05 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000672,131Mar 05 06:27 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,813052,316Mar 05 06:33 PM
MITCHELL PAUL JDirectorMar 01Option Exercise11.441,00011,4409,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 01Option Exercise0.005,250051,837Mar 05 06:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000666,910Mar 05 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000172,111Mar 05 06:16 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250036,145Mar 05 06:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500083,882Mar 05 06:02 PM
Cooke ShanePresident, Alkermes plcMar 01Option Exercise0.007,000085,992Mar 05 05:55 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 01Option Exercise0.005,750040,463Mar 05 05:46 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250021,677Mar 05 05:35 PM
MITCHELL PAUL JDirectorMar 01Sale57.041,00057,0408,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 26Option Exercise0.002,625047,754Feb 28 06:46 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000653,855Feb 28 06:42 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250168,385Feb 28 06:37 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100034,219Feb 28 06:30 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625080,156Feb 28 06:18 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100019,751Feb 28 05:49 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425081,293Feb 28 05:54 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 26Option Exercise0.003,750035,818Feb 28 05:40 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 20Option Exercise17.9917,242310,18432,068Feb 21 05:37 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500646,436Feb 21 06:07 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 17Option Exercise0.003,000047,013Feb 21 06:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000166,693Feb 21 06:01 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,0000147,039Feb 21 05:55 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500033,907Feb 21 06:00 PM
Cooke ShanePresident, Alkermes plcFeb 17Option Exercise0.004,500079,208Feb 21 05:51 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500019,443Feb 21 05:44 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 17Option Exercise0.003,750015,974Feb 21 05:37 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Option Exercise17.3010,880188,22454,893Feb 21 06:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Sale70.5010,880767,09244,013Feb 21 06:10 PM
Cooke ShanePresident, Alkermes plcFeb 02Option Exercise16.5572,7931,204,724147,501Feb 02 06:07 PM
Cooke ShanePresident, Alkermes plcFeb 02Sale60.5572,7934,407,67974,708Feb 02 06:07 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise11.441,00011,4409,000Feb 02 06:04 PM
MITCHELL PAUL JDirectorFeb 01Sale56.771,00056,7708,000Feb 02 06:04 PM
Cooke ShanePresident, Alkermes plcJan 29Option Exercise16.553,30054,61578,008Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 29Sale60.003,300198,00074,708Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Option Exercise16.551,70028,13576,408Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Sale60.021,700102,02874,708Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 11Option Exercise16.556,207102,72680,915Jan 16 06:30 PM
Cooke ShanePresident, Alkermes plcJan 11Sale60.226,207373,80974,708Jan 16 06:30 PM
MITCHELL PAUL JDirectorJan 02Option Exercise11.441,00011,4409,000Jan 03 05:11 PM
MITCHELL PAUL JDirectorJan 02Sale54.991,00054,9908,000Jan 03 05:11 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Dec 29Sale54.8110,652583,88616,943Jan 02 06:28 PM
ANSTICE DAVID WDirectorDec 13Option Exercise11.4440,000457,60055,000Dec 14 05:26 PM
MITCHELL PAUL JDirectorDec 01Option Exercise11.441,00011,4409,000Dec 01 05:32 PM
MITCHELL PAUL JDirectorDec 01Sale51.981,00051,9808,000Dec 01 05:32 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 29Option Exercise12.2920,932257,254164,971Nov 30 06:18 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 29Sale50.5120,9321,057,249144,039Nov 30 06:18 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 08Option Exercise12.2920,932257,254164,971Nov 09 05:07 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 08Sale47.5820,932996,009144,039Nov 09 05:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 02Option Exercise14.1350,000706,500687,686Nov 03 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 02Sale48.8750,0002,443,410637,686Nov 03 05:19 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 01Option Exercise14.1315,000211,950178,693Nov 03 05:13 PM
MITCHELL PAUL JDirectorNov 01Option Exercise11.441,00011,4409,000Nov 03 05:17 PM
MITCHELL PAUL JDirectorNov 01Sale49.161,00049,1608,000Nov 03 05:17 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 01Sale48.7115,000730,688163,693Nov 03 05:13 PM
MITCHELL PAUL JDirectorOct 02Option Exercise11.441,50017,1609,500Oct 04 05:06 PM
MITCHELL PAUL JDirectorOct 02Sale50.641,50075,9608,000Oct 04 05:06 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 15Option Exercise15.475,80589,77461,589Sep 18 06:08 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 15Option Exercise14.132503,53331,407Sep 18 05:13 PM
BLOOM FLOYD EDirectorSep 12Option Exercise11.4420,000228,80020,000Sep 14 05:22 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 11Option Exercise14.1313,566191,68870,455Sep 13 05:36 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 11Sale51.2913,566695,81756,889Sep 13 05:36 PM
MITCHELL PAUL JDirectorSep 01Option Exercise11.441,50017,1609,500Sep 05 05:09 PM
MITCHELL PAUL JDirectorSep 01Sale50.771,50076,1558,000Sep 05 05:09 PM
MITCHELL PAUL JDirectorAug 01Option Exercise11.441,50017,1609,500Aug 01 05:12 PM
MITCHELL PAUL JDirectorAug 01Sale54.911,50082,3658,000Aug 01 05:12 PM
MITCHELL PAUL JDirectorJul 03Option Exercise11.441,50017,1609,500Jul 06 05:36 PM
MITCHELL PAUL JDirectorJul 03Sale58.111,50087,1658,000Jul 06 05:36 PM
Cooke ShanePresident, Alkermes plcJun 08Option Exercise16.5510,000165,50084,708Jun 08 05:33 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Option Exercise17.3010,000173,00054,013Jun 08 05:41 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Sale60.3410,000603,35244,013Jun 08 05:41 PM
Cooke ShanePresident, Alkermes plcJun 08Sale60.3310,000603,33374,708Jun 08 05:33 PM
MITCHELL PAUL JDirectorJun 01Option Exercise11.441,50017,1609,500Jun 01 05:21 PM
MITCHELL PAUL JDirectorJun 01Sale57.491,50086,2358,000Jun 01 05:21 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMay 28Option Exercise0.002,500044,013May 30 05:51 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 28Option Exercise0.0013,7500644,156May 30 05:49 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000164,870May 30 05:46 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 28Option Exercise0.001,250031,563May 30 05:42 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 28Option Exercise0.002,5000130,654May 30 05:39 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750058,821May 30 05:30 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750077,698May 30 05:23 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 28Option Exercise0.001,750028,163May 30 05:20 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMay 28Option Exercise0.003,750058,654May 30 05:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Option Exercise15.9525,000398,750655,406May 25 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Sale57.4225,0001,435,535630,406May 25 05:34 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Option Exercise15.9510,000159,500172,370May 19 05:58 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Sale57.2310,000572,254162,370May 19 05:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Option Exercise15.9550,000797,500680,406May 19 05:28 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 17Option Exercise15.952,25035,88830,313May 19 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Sale58.1950,0002,909,439630,406May 19 05:28 PM